The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Furtulon     1-[(2R,3R,4S,5R)-3,4- dihydroxy-5-methyl...

Synonyms: Flutron, Doxifluridina, doxifluridine, doxyfluridine, Doxifluridinum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Flutron


High impact information on Flutron


Chemical compound and disease context of Flutron


Biological context of Flutron


Anatomical context of Flutron


Associations of Flutron with other chemical compounds


Gene context of Flutron


Analytical, diagnostic and therapeutic context of Flutron


  1. Phase II study of doxifluridine in advanced colorectal adenocarcinoma. Abele, R., Alberto, P., Kaplan, S., Siegenthaler, P., Hofmann, V., Ryssel, H.J., Hartmann, D., Holdener, E.E., Cavalli, F. J. Clin. Oncol. (1983) [Pubmed]
  2. Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. Tominaga, T., Koyama, H., Toge, T., Miura, S., Sugimachi, K., Yamaguchi, S., Hirata, K., Monden, Y., Nomura, Y., Toi, M., Kimijima, I., Noguchi, S., Sonoo, H., Asaishi, K., Ikeda, T., Morimoto, T., Ota, J., Ohashi, Y., Abe, O. J. Clin. Oncol. (2003) [Pubmed]
  3. 5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. Armstrong, R.D., Cadman, E. Cancer Res. (1983) [Pubmed]
  4. Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. de Bruijn, E.A., van Oosterom, A.T., Tjaden, U.R., Reeuwijk, H.J., Pinedo, H.M. Cancer Res. (1985) [Pubmed]
  5. Role of administration route in the therapeutic efficacy of doxifluridine. Trave, F., Canobbio, L., Au, J.L., Rustum, Y.M. J. Natl. Cancer Inst. (1987) [Pubmed]
  6. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Haraguchi, M., Furukawa, T., Sumizawa, T., Akiyama, S. Cancer Res. (1993) [Pubmed]
  7. Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Tanaka, Y., Eda, H., Fujimoto, K., Tanaka, T., Ishikawa, T., Ishitsuka, H. Cancer Res. (1990) [Pubmed]
  8. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Fujimoto-Ouchi, K., Tanaka, Y., Tominaga, T. Clin. Cancer Res. (2001) [Pubmed]
  9. A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer. Min, J.S., Kim, N.K., Park, J.K., Yun, S.H., Noh, J.K. Ann. Surg. Oncol. (2000) [Pubmed]
  10. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Terashima, M., Fujiwara, H., Takagane, A., Abe, K., Araya, M., Irinoda, T., Yonezawa, H., Nakaya, T., Oyama, K., Takahashi, M., Saito, K. Eur. J. Cancer (2002) [Pubmed]
  11. Preoperative chemoradiotherapy with oral doxifluridine plus low-dose oral leucovorin in unresectable primary rectal cancer. Seong, J., Cho, J.H., Kim, N.K., Min, J.S., Suh, C.O. Int. J. Radiat. Oncol. Biol. Phys. (2001) [Pubmed]
  12. Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Alberto, P. Ann. Oncol. (1993) [Pubmed]
  13. Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans. Sommadossi, J.P., Aubert, C., Cano, J.P., Gouveia, J., Ribaud, P., Mathé, G. Cancer Res. (1983) [Pubmed]
  14. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Twelves, C., Glynne-Jones, R., Cassidy, J., Schüller, J., Goggin, T., Roos, B., Banken, L., Utoh, M., Weidekamm, E., Reigner, B. Clin. Cancer Res. (1999) [Pubmed]
  15. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Magné, N., Fischel, J.L., Dubreuil, A., Formento, P., Ciccolini, J., Formento, J.L., Tiffon, C., Renée, N., Marchetti, S., Etienne, M.C., Milano, G. Clin. Cancer Res. (2003) [Pubmed]
  16. Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro. Eliason, J.F., Ramuz, H., Yoshikubo, T., Ishikawa, T., Yamamoto, T., Tsuruo, T. Biochem. Pharmacol. (1995) [Pubmed]
  17. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Temmink, O.H., de Bruin, M., Turksma, A.W., Cricca, S., Laan, A.C., Peters, G.J. Int. J. Biochem. Cell Biol. (2007) [Pubmed]
  18. Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. Stevenson, D.P., Collins, W.P., Farzaneh, F., Hata, K., Miyazaki, K. Am. J. Pathol. (1998) [Pubmed]
  19. Activation and cytotoxicity of 5'-deoxy-5-fluorouridine in c-H-ras transformed NIH 3T3 cells. Geng, Y., Gheuens, E., de Bruijn, E.A. Biochem. Pharmacol. (1991) [Pubmed]
  20. Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia. Au, J.L., Rustum, Y.M., Minowada, J., Srivastava, B.I. Biochem. Pharmacol. (1983) [Pubmed]
  21. Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. Inoue, Y., Shirane, M., Miki, C., Hiro, J., Tanaka, K., Kobayashi, M., Mori, K., Yanagi, H., Kusunoki, M. Int. J. Oncol. (2004) [Pubmed]
  22. Determination of N3-methyl-5'-deoxy-5-fluorouridine, a novel metabolite of doxifluridine, in body fluids by high performance liquid chromatography. Zambonin, C.G., Mastrolitti, S., Palmisano, F. Journal of pharmaceutical and biomedical analysis. (1998) [Pubmed]
  23. Antiproliferative action of a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine, measured in vitro and in vivo on four different murine tumor lines. Hartmann, H.R., Matter, A. Cancer Res. (1982) [Pubmed]
  24. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Sawada, N., Ishikawa, T., Sekiguchi, F., Tanaka, Y., Ishitsuka, H. Clin. Cancer Res. (1999) [Pubmed]
  25. Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. Nagata, T., Nakamori, M., Iwahashi, M., Yamaue, H. Eur. J. Cancer (2002) [Pubmed]
  26. Stimulatory effects of EGF and TGF-alpha on invasive activity and 5'-deoxy-5-fluorouridine sensitivity in uterine cervical-carcinoma SKG-IIIb cells. Ueda, M., Ueki, M., Terai, Y., Morimoto, A., Fujii, H., Yoshizawa, K., Yanagihara, T. Int. J. Cancer (1997) [Pubmed]
  27. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival. Tanaka-Nozaki, M., Tajiri, T., Tanaka, N., Furukawa, K., Takasaki, H., Yoshimura, K., Suzuki, H., Naito, Z., Sugizaki, Y., Merk, H.F., Blömeke, B., Kato, S. Oncol. Rep. (2003) [Pubmed]
  28. Expression of extracellular signal-regulated kinase and its relationship with clinicopathological characteristics of breast cancer. Wang, Z., Wang, S., Zhu, F., Ye, Y., Yu, Y., Qiao, X. Zhonghua Zhong Liu Za Zhi (2002) [Pubmed]
  29. Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes. Mimori, K., Ueo, H., Kuroki, T., Shiraishi, T., Creer, S., Taylor, S., Ishii, H., Mori, M. Oncol. Rep. (2004) [Pubmed]
  30. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Eda, H., Fujimoto, K., Watanabe, S., Ura, M., Hino, A., Tanaka, Y., Wada, K., Ishitsuka, H. Cancer Chemother. Pharmacol. (1993) [Pubmed]
  31. Simultaneous occurrence of adenomas in stomach, duodenal bulb, and colon: disappearance of gastric and duodenal adenomas during oral administration of 5'-deoxy-5-fluorouridine. Wada, M., Jin, H., Kinugasa, A., Shintani, S., Sawada, K., Yamashita, M., Yamamura, M., Nishigami, T., Kano, M., Shimoyama, T. Am. J. Gastroenterol. (1994) [Pubmed]
  32. Interferon alpha and 5'-deoxy-5-fluorouridine in colon cancer: effects as single agents and in combination on growth of xenograft tumours. Laurent, P.L., Tevaearai, H.T., Eliason, J.F., Givel, J.C., Odartchenko, N. Eur. J. Cancer (1994) [Pubmed]
WikiGenes - Universities